Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
The purpose of this study is to determine whether insulin administered by a subcutaneous
 injection is effective in the treatment of a diabetic crisis and to determine if
 beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.
Inclusion Criteria: age 18 or older

 -  venous pH < 7.3 or arterial < 7.35

 -  at least 2 of the following 3:

 1. serum HCO3 < 18/anion gap > 16

 2. serum glucose > 300 mg/dl

 3. serum acetone positive

 Exclusion Criteria:

 -  pregnant

 -  less than age 18